Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30350539 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2CA12CA1CA2CA7 | |
| Cyanide SCHEMBL27389366 | 0.94 | SMN1; SMN2 (0.45) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL9376529 | 0.92 | SMN1; SMN2 (0.44) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL3648629 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL25434306 | 0.82 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL151213 | 0.82 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL27753904 | 0.82 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL3711484 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL22588491 | 0.80 | MAPK1 (0.48) | SMN1; SMN2CA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL31658961 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398152-B2 | Thioxanthone derivatives, composition comprising the same and pattern forming method comprising said composition | LINTFIELD LIMITED (GB) | 2025-08-26 | — | — | US | disclosed |
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ONCOLYS BIOPHARMA, INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ONCOLYS BIOPHARMA, INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| CN-107567443-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-28 | — | — | CN | disclosed |
| CN-115925679-A | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-07 | — | — | CN | disclosed |
| EP-4154884-A1 | ANTI-SARS-COV-2 DURG | Oncolys BioPharma, Inc. (JP) | 2023-03-29 | — | — | EP | disclosed |
| EP-3239143-B1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEMICAL LTD (KR) | 2023-03-22 | — | — | EP | disclosed |
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEM, LTD. (KR) | 2022-05-05 | — | — | US | disclosed |
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | LG CHEM. LTD. (KR) | 2022-03-01 | — | — | US | disclosed |
| US-20210277017-A1 | Thioxanthone Derivatives, Composition Comprising the Same and Pattern Forming Method Comprising Said Composition | LINTFIELD LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| US-6048842-A | ANTIDIABETIC AGENT | TANABE SEIYAKU CO., LTD. (JP) | 2000-04-11 | — | — | US | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0850948-A1 | Propiophenone derivatives and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1998-07-01 | — | — | EP | disclosed |
| EP-0584222-B1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE POULENC RORER INT (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5656643-A | QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ACE2, ACE, SARS1 | SMN1; SMN2 4289/4885CA12 1337/4885CA1 4223/4885 |
| US-12398152-B2 | Thioxanthone derivatives, composition comprising the same and pattern forming method comprising said composition | TPMT, TST, PPOX | SMN1; SMN2 4881/4885CA12 2777/4885CA1 3798/4885 |
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | GPR119, GLP1R, GIPR | SMN1; SMN2 3448/4885CA12 4663/4885CA1 4658/4885 |
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | GPR119, GPR88, FFAR1 | SMN1; SMN2 4496/4885CA12 4774/4885CA1 4805/4885 |
| US-20210277017-A1 | Thioxanthone Derivatives, Composition Comprising the Same and Pattern Forming Method Comprising Said Composition | TPMT, TST, PPOX | SMN1; SMN2 4881/4885CA12 2777/4885CA1 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.